Current Report Filing (8-k)
01 July 2017 - 3:36AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 26, 2017
AMERICAN BIO MEDICA
CORPORATION
(Exact name of registrant as specified in
its charter)
New York
|
|
0-28666
|
|
14-1702188
|
(State or other jurisdiction of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification Number)
|
122 Smith Road, Kinderhook, NY
12106
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including
area code: 518-758-8158
Not applicable
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction
A.2. below):
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 5.02 Departure of Directors or
Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On June 26, 2017, upon
recommendation of American Bio Medica Corporation’s (the “Company”) Nominating Committee of the Board of Directors,
the Board of Directors appointed Chaim Davis to fill a board seat vacancy created by the resignation of Carl A. Florio on April
6, 2017. Mr. Davis was also appointed to the Compensation, Audit and Nominating Committees of the Company’s Board of Directors.
Since July 2005, Mr.
Davis has been the Managing Member of Revach Group, LLC, the general partner of Revach Fund L.P. (“Revach”), a sector-specific
life science fund focusing on micro to mid cap companies, which he founded in 2005. He has also served as a consultant to other
hedge funds including Gem Partners, KOM Capital Management and Maot Group. From 2010 to 2014, he served as a director and a member
of the audit and compensation committees of AtheroNova Inc. (OTCBQ: AHRO), and from 2001 to 2004, he served as a healthcare analyst
at The Garnet Group. Mr. Davis received his B.A. from Columbia University. Since April 2013, Mr. Davis has also served on the Board
of Directors of Entera Bio, a clinical stage biopharmaceutical company. There are no material arrangements, including compensation
arrangements, between Mr. Davis and the Company other than customary compensation to board members.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AMERICAN BIO MEDICA CORPORATION (Registrant)
|
|
|
|
|
|
|
|
|
Dated: June 30, 2017
|
By:
|
/s/ Melissa A. Waterhouse
|
|
|
|
Melissa A. Waterhouse
|
|
|
|
Chief Executive Officer (Principal Executive Officer)
|
|
|
Principal Financial Officer
|
|
American Bio Medica (CE) (USOTC:ABMC)
Historical Stock Chart
From Apr 2024 to May 2024
American Bio Medica (CE) (USOTC:ABMC)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about American Bio Medica Corporation (CE) (OTCMarkets): 0 recent articles
More American Bio Medica Corp News Articles